Physician profile
Peter Wu
NPI 1558682492
$3,302.26
in general payments reported to CMS, 2019-2025
14 companies · $825 in 2025
The $825 reported for 2025 was more than what 83% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $268 · 2022: $15.63 · 2023: $194 · 2024: $978 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $499.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $497.68 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $343.77 | 2024-2025 | Auvelity |
| Allergan, INC. | $295.30 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $258.43 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $243.60 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $243.34 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $203.39 | 2019-2020 | |
| Corium, LLC | $183.08 | 2023-2024 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $148.40 | 2024 | Spravato |
| Tris Pharma INC | $140.75 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $125.31 | 2019 | |
| Abbvie INC. | $94.16 | 2024 | |
| Sunovion Pharmaceuticals INC. | $25.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.